Biomarkers Market (Diagnostic Applications in Risk Assessment, Molecular Diagnostics, Disease Diagnosis, Drug Discovery & Development, Drug Formulation, Forensic Applications and Others) - Global Industry Analysis, Emerging Technologies, Competitive Intel

NEW YORK, Jan. 15, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biomarkers Market (Diagnostic Applications in Risk Assessment, Molecular Diagnostics, Disease Diagnosis, Drug Discovery & Development, Drug Formulation, Forensic Applications and Others) - Global Industry Analysis, Emerging Technologies, Competitive Intel
http://www.reportlinker.com/p01939928/Biomarkers-Market-Diagnostic-Applications-in-Risk-Assessment-Molecular-Diagnostics-Disease-Diagnosis-Drug-Discovery--Development-Drug-Formulation-Forensic-Applications-and-Others---Global-Industry-Analysis-Emerging-Technologies-Competitive-Intel.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

Biomarkers Market (Diagnostic Applications in Risk Assessment, Molecular Diagnostics, Disease Diagnosis, Drug Discovery & Development, Drug Formulation, Forensic Applications and Others) - Global Industry Analysis, Emerging Technologies, Competitive Intelligence, Growth Trends, Size, Share, Opportunities and Forecast, 2013 - 2020

Biomarker technology is evidencing increased application from key segments such as disease diagnosis, drug development and formulation, diagnosis for exposure of certain harmful chemical and prognostic treatments. Biomarkers are novel diagnostic solutions and advancement in it its development and understanding of human genome promotes its application in diagnosis of disease on molecular basis. Pharmaceutical companies which are interested in introducing novel diagnostic solution are increasing partnership and collaboration with private laboratories, educational institute and these companies are also increasing their investments in research and development.

The global market for diagnostic biomarker expected to reach about $30.6 billion in 2020 growing at CAGR of 16% from 2013 to 2020. Disease diagnostic application remains the key area of application that is expected to reach 6.1 $billion in 2020. However application of diagnostic biomarkers in forensics and molecular diagnostics is catching up quite significantly. Molecular diagnostics is expected to grow at a CAGR of 17.6% from 2013 to 2020.

Scope

Global diagnostic Biomarker report segments the market in three categories; market by technologies, market by services, and market by diseases. These markets are expected to show elevated growth in future as biomarkers are providing diagnostic service for complex disease. As it is non-invasive procedure it motivates the use of biomarkers than conventional diagnostic applications. This report focuses on key factors impacting the diagnostic biomarker market used in risk assessment, molecular diagnostics, disease diagnosis, drug discovery and development, drug formulation, forensic applications and others. Diagnostic biomarker and its applications in emerging segments of omics, imaging technologies, personalized medicine, and bioinformatics are all discussed in detail.

Key deliverables

Biomarkers of disease are majorly covered by oncology, cardiovascular and Neurology disease. Oncology biomarkers are covering more market share as compared to other disease biomarkers. Other biomarker are facing some ethical and technical problem such complex sample preparation process.

Biomarkers in service has open a new market for sample preparation for disease diagnosis which enables clinicians to save time required for preparing sample to conduct diagnostic test. Biomarkers are also resolving drug validation problem by analyzing viability of drug discovered by pharmaceutical research.

The geographic analysis is based on North America., Europe, Asia-Pacific and Rest of the World.

The key players in this market that are also profiled in the report include Roche Diagnostic Limited (Switzerland), Siemens Healthcare (Germany), Abbott Laboratories Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), Aushon BioSystem Inc. (M.A.), Epistem Ltd.(U.K.), G.E. Healthcare Inc.(U.K).

Key benefits of report

Assessment and ranking the factors that favour the market growth and those factors which act as a hindrance for the growth of the market
The market sizing and estimation period is from 2013 to 2020. Two historic years include 2011 and 2012
The report identifies and analyses top investment pockets and top winning strategies for diagnostic biomarker market
The report analyses the various strategies adopted by some of the key companies in the market
The report tracks and analyses key innovations and patents for biomarkers in the last five years

1. Introduction
1.1 Scope and Coverage

1.2 Report Description

2 Executive Summary

2.1 Biomarker Diagnosis Vs. Conventional Diagnosis

2.2 Why Diagnostic Biomarkers are Used in Diagnosis and Drug Development?

3 Market Overview

3.1 Key Application of Diagnostic Biomarkers in Top Technologies

3.1.1 Omics Technology

3.1.1.1 Applications of Omics Technology

3.1.1.1.1 Lung Disease Identification

3.1.1.1.2 Quantifying Abnormalities

3.1.1.1.3 Genetic Trait Diagnosis

3.1.1.1.4 Analyzing Drug Efficiency

3.1.1.1.5 Functional Food Development

3.1.1.1.6 Pharmacogenomics

3.1.1.1.7 Drivers

3.1.1.1.8 Restraints

3.1.1.1.8.1 Lengthy Process

3.1.1.1.8.2 Ethical Problems

3.1.1.1.8.3 Sample Collection

3.1.1.1.8.4 Gene Expression

3.1.1.1.8.5 Inefficiency in Pre-Disease Identification

3.1.2 Imaging Technology

3.1.2.1 Application of Diagnostic Imaging Technology

3.1.2.2 Drivers

3.1.2.2.1 Faster Test Result

3.1.2.2.2 Improved Nursing Services

3.1.2.2.3 Noninvasive Technique

3.1.2.3 Restraints

3.1.2.3.1 Radiation Effect

3.1.2.3.2 Complex Process

3.1.2.3.3 Genetic Variation

3.1.2.4 Trends

3.1.3 Bioinformatics

3.1.3.1 Applications of Bioinformatics

3.1.3.2 Drivers

3.1.3.2.1 Open Source of Information

3.1.3.2.2 Relevant Information

3.1.3.2.3 Forecasting of Information

3.1.3.3 Restraints

3.1.3.3.1 Difficulty in Practical Application

3.1.3.3.2 Over-Fitting

3.1.3.3.3 Complex Operation Process

3.1.3.3.4 Security Issue

3.1.3.3.5 Costly Management

3.1.3.3.6 Virtual Storage

3.1.4 Personalized Medicines

3.1.4.1 Drivers

3.1.4.1.1 Unique Solution

3.1.4.1.2 Minimal Invasive

3.1.4.1.3 Reduction in Failure

3.1.4.1.4 Effective Prescription

3.1.4.2 Restraints

3.1.4.2.1 Need Specialized Setup for Treatment

3.1.4.2.2 Liability Issue

3.1.4.2.3 Ethical Question

3.1.5 Others (Nutritional Technology)

3.2 Importance of Non-Invasive Diagnostics

3.3 Key Advantages of Dm

3.4 Regulatory Scenario

3.5 Reimbursement Issues

3.6 Key Patents and Analysis

3.7 Top Ten Factors Impacting DBM Market

3.7.1 Non-Invasive Technique

3.7.2 Drug Discovery and Development

3.7.3 Cost Effective Tool for Diagnosis

3.7.4 Multi-Marker Application

3.7.5 Accuracy and Reliability

3.7.6 Ethical Issues

3.7.7 Gene Level Diagnosis

3.7.8 Complex Processes

3.7.9 Government Regulations

3.7.10 Reimbursement Issues

3.8 Top Investment Pockets

3.9 Market Intelligence

3.9.1 Top Three Winning Strategies

3.9.1.1 Product Launch

3.9.1.2 Collaboration and Agreement

3.9.1.3 Merger and Acquisition

3.10 Market Dynamics

3.10.1 Drivers

3.10.1.1 Cost Effective

3.10.1.2 Non-Invasive

3.10.1.3 Accuracy in Result

3.10.1.4 Assistant in Clinical Trials

3.10.1.5 Multi-Marker Application

3.10.1.6 Gene Level Diagnosis

3.10.2 Restrains

3.10.2.1 Government Regulation

3.10.2.2 Ethical Problems

3.10.2.3 Conformation in Result

3.10.2.4 Complex Process

3.10.3 Opportunity

3.10.3.1 Local Market

3.10.3.2 Personalized Medicine

3.10.3.3 Tissue Specific Treatment

4 Global Diagnostic Biomarker Market by Types

4.1 Biomarker of Exposure

4.2 Biomarkers of Disease

5 Global Diagnostic Biomarker Market by Applications

5.1 Risk Assessment

5.1.1 Applications

5.1.1.1 Oncology Treatment

5.1.1.2 Cardiovascular Treatment

5.1.2 Drivers

5.1.2.1 Forecasting of Abnormal Conditions

5.1.2.2 Cost Effective

5.1.3 Restraints

5.1.3.1 Government Regulations

5.1.3.2 Ethical Issues

5.2 Development of Molecular Diagnostic

5.2.1 Application

5.2.1.1 Prenatal Diagnostics

5.2.1.2 Human Clinical Molecular Diagnostic Testing

5.2.1.3 Veterinary Molecular Diagnostic Testing

5.2.1.4 Identity Testing

5.2.1.5 Histocompatibility Testing

5.2.2 Drivers

5.2.2.1 Uniformity in Test Result

5.2.2.2 Cost Effective

5.2.2.3 Fast Result

5.2.2.4 More Profitable

5.2.2.5 Automation

5.2.3 Restraints

5.2.3.1 Not Applicable for Twins Genomes

5.2.3.2 Government Regulations

5.2.3.3 Ethical Issues

5.3 Disease Diagnosis

5.3.1 Oncology

5.3.1.1 Drivers

5.3.1.2 Restraints

5.3.1.2.1 Complex Process

5.3.1.2.2 Conformation in Result

5.3.1.2.3 Used for Early Diagnosis Only

5.3.2 Cardiology

5.3.2.1 Application

5.3.2.2 Drivers

5.3.2.2.1 Cost Effective

5.3.2.2.2 Tissue Specific

5.3.2.2.3 Accurate Result

5.3.2.3 Restraints

5.3.2.3.1 Loss of Specificity

5.3.2.3.2 Low Specificity

5.3.2.3.3 Low Sensitivity

5.3.3 Neurology

5.3.3.1 Application

5.3.3.2 Drivers

5.3.3.2.1 Relevant Information

5.3.3.2.2 Efficient Diagnosis

5.3.3.2.3 Assistant in Clinical Trials

5.3.3.3 Restraints

5.3.3.3.1 Complex Process

5.3.3.3.2 Chromosomal Variation

5.3.3.3.3 Hurdles in Tracking

5.3.3.4 Alzheimer's

5.3.3.5 Multiple Sclerosis

5.3.3.6 Parkinson's Disease

5.3.3.7 Others (Renal Diseases, Urinal Disease)

5.4 Drug Discovery and Development

5.4.1 Application

5.4.2 Drivers

5.4.2.1 Increased Efficiency

5.4.2.2 High Quality Support

5.4.2.3 Cost Effective

5.4.2.4 Collaboration for Novel Development

5.4.3 Restraints

5.4.3.1 Drug Metabolism

5.4.3.2 Stability of Biomarkers

5.4.3.3 Complex Process

5.5 Drug Formulation

5.5.1 Application

5.5.2 Drivers

5.5.3 Restraint

5.6 Forensic Application

5.7 Others (Dna Fingerprinting and Others)

5.7.1 Blood Alcohol Concentration Biomarker

5.7.2 Dna Fingerprinting

6 Global Diagnostic Biomarker Market by Services

6.1 Sample Preparation

6.1.1 Application

6.1.1.1 Biological Mass Spectrometry

6.1.2 Drivers

6.1.2.1 Cost Effective

6.1.2.2 Sample Rigidity

6.1.2.3 Efficient Forensic Studies

6.1.3 Restraints

6.1.3.1 Complex Structure

6.1.3.2 Lack of Effectiveness

6.1.3.3 Extensive Fractionation

6.1.3.4 Loss of Biological Compounds

6.2 Assay Development

6.2.1 Application

6.2.1.1 Clinical Trials

6.2.1.2 Drug Development and Validation

6.2.1.3 Others

6.2.2 Drivers

6.2.2.1 Accuracy

6.2.2.2 Cost Effective

6.2.2.3 Timely Result

6.2.3 Restraints

6.2.3.1 Complexity in Technique

6.2.3.2 Tissue Specific

6.3 Biomarker Validation and Testing

6.3.1 Drivers

6.3.1.1 Reduce Failure Rate

6.3.2 Restraints

6.3.2.1 Clinical Errors

6.3.2.2 Time Consuming

6.4 Other Services

7 Global Diagnostic Biomarker Market by Geography

7.1 North America

7.2 Europe

7.3 Asia-Pacific

7.4 Row (Rest of World)

8 Competitive Landscape

8.1 Product Launch

8.1.1 Recent Development

8.2 Collaboration and Partnership

8.2.1 Recent Development

8.3 Clearance and Approval

8.3.1 Recent Development

8.4 Mergers and Acquisition

8.4.1 Recent Development

9 Company Profile

9.1 Abbott Laboratories, Inc.

9.1.1 Company Overview

9.1.2 Company Snapshot

9.1.3 Business Performance

9.1.4 Strategic Moves and Developments

9.1.4.1 Principal Strategies

9.1.4.2 Secondary Strategies

9.1.5 Swot Analysis & Strategic Conclusions

9.2 Agilent Technologies Inc.

9.2.1 Company Overview

9.2.2 Company Snapshot

9.2.3 Business Performance

9.2.4 Strategic Moves and Developments

9.2.4.1 Primary Strategies

9.2.4.2 Secondary Strategies

9.2.5 Swot Analysis & Strategic Conclusions

9.3 Aushon Biosystem

9.3.1 Company Profile

9.3.2 Company Snapshot

9.3.3 Strategic Moves and Developments

9.3.3.1 Primary Strategies

9.3.3.2 Secondary Strategies

9.3.4 Swot Analysis & Strategic Conclusions

9.4 Bio-Rad Laboratories

9.4.1 Company Profile

9.4.2 Company Snapshot

9.4.3 Business Performance

9.4.4 Strategic Moves and Developments

9.4.4.1 Primary Strategies

9.4.4.2 Secondary Strategies

9.4.5 Swot Analysis & Strategic Conclusions

9.5 Eisai Co. Ltd.

9.5.1 Company Profile

9.5.2 Company Snapshot

9.5.3 Business Performance

9.5.4 Strategic Moves and Developments

9.5.4.1 Primary Strategies

9.5.4.2 Secondary Strategies

9.5.5 Swot Analysis & Strategic Conclusions

9.6 Epistem Ltd.

9.6.1 Company Profile

9.6.2 Company Snapshot

9.6.3 Business Performance

9.6.4 Strategic Moves and Developments

9.6.4.1 Primary Strategies

9.6.4.2 Secondary Strategies

9.6.5 Swot Analysis & Strategic Conclusions

9.7 Ge Healthcare

9.7.1 Company Profile

9.7.2 Company Snapshot

9.7.3 Business Performance

9.7.4 Strategic Moves and Developments

9.7.4.1 Principle Strategies

9.7.4.2 Secondary Strategies

9.7.5 Swot Analysis & Strategic Conclusions

9.8 Roche Diagnostics Limited

9.8.1 Company Profile

9.8.2 Company Snapshot

9.8.3 Business Performance

9.8.4 Strategic Moves and Developments

9.8.4.1 Principal Strategies

9.8.4.2 Secondary Strategies

9.8.5 Swot Analysis & Strategic Conclusions

9.9 Siemens AG

9.9.1 Company Profile

9.9.2 Company Snapshot

9.9.3 Business Performance

9.9.4 Strategic Moves and Developments

9.9.4.1 Primary Strategies

9.9.4.2 Secondary Strategies

9.9.5 Swot Analysis & Strategic Conclusions

9.10 Thermo Fisher Scientific Inc.

9.10.1 Company Profile

9.10.2 Company Snapshot

9.10.3 Business Performance

9.10.4 Strategic Moves and Developments

9.10.4.1 Primary Strategies

9.10.4.2 Secondary Strategies

9.10.5 Swot Analysis & Strategic Conclusions

Companies Mentioned

Abbott Laboratories, Inc, Agilent Technologies Inc., Aushon Biosystem, Bio-Rad Laboratories,  Eisai Co. Ltd., Epistem Ltd., Ge Healthcare, Roche Diagnostics Limited, Siemens AG and Thermo Fisher Scientific Inc.

To order this report: Biomarkers Market (Diagnostic Applications in Risk Assessment, Molecular Diagnostics, Disease Diagnosis, Drug Discovery & Development, Drug Formulation, Forensic Applications and Others) - Global Industry Analysis, Emerging Technologies, Competitive Intel
http://www.reportlinker.com/p01939928/Biomarkers-Market-Diagnostic-Applications-in-Risk-Assessment-Molecular-Diagnostics-Disease-Diagnosis-Drug-Discovery--Development-Drug-Formulation-Forensic-Applications-and-Others---Global-Industry-Analysis-Emerging-Technologies-Competitive-Intel.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker